Gensight Biologics SA (SIGHT) — Cash Flow-to-Debt Ratio
Gensight Biologics SA (SIGHT) has a Cash Flow-to-Debt Ratio of -0.20x as of December 2025, meaning its operating cash flow of €-6.49 Million could theoretically repay 0% of its total liabilities (€33.20 Million) in one year. Explore SIGHT cash flow conversion to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Gensight Biologics SA Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Gensight Biologics SA across 13 annual periods. Also explore balance sheet size of Gensight Biologics SA for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Gensight Biologics SA (2013–2025)
Year-by-year debt coverage analysis for Gensight Biologics SA. For market capitalisation and broader financial context, see SIGHT company net worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.28x | €-9.38 Million | €33.20 Million | ▲ +17.7% |
| 2024 | -0.34x | €-12.94 Million | €37.68 Million | ▲ +44.5% |
| 2023 | -0.62x | €-24.66 Million | €39.83 Million | ▲ +24.4% |
| 2022 | -0.82x | €-33.75 Million | €41.22 Million | ▼ -94.3% |
| 2021 | -0.42x | €-17.14 Million | €40.66 Million | ▼ 0.0% |
| 2020 | -0.42x | €-15.04 Million | €35.69 Million | ▲ +68.9% |
| 2019 | -1.36x | €-28.11 Million | €20.74 Million | ▲ +37.4% |
| 2018 | -2.17x | €-28.38 Million | €13.11 Million | ▲ +16.8% |
| 2017 | -2.60x | €-18.78 Million | €7.22 Million | ▲ +21.9% |
| 2016 | -3.33x | €-19.64 Million | €5.89 Million | ▼ -92.6% |
| 2015 | -1.73x | €-12.09 Million | €6.98 Million | ▼ -33.0% |
| 2014 | -1.30x | €-5.52 Million | €4.24 Million | ▼ -27.2% |
| 2013 | -1.02x | €-1.95 Million | €1.91 Million | — |